CASRAI Dictionary

Tag: concordat to support research integrity

  • Research Misconduct Lawyer: Do You Need One?

    A research misconduct lawyer is a solicitor, barrister, or (in the US) an attorney who advises a researcher through an allegation of fabrication, falsification, or plagiarism — from the initial screening through formal investigation, any disciplinary hearing, and appeal. Legal counsel becomes advisable once an allegation is put in writing, and becomes necessary where funding, employment, professional registration, or a potential fraud referral is at stake.

    Research misconduct is fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results — a definition set out in US federal regulation and mirrored across UK institutional policies aligned to the Concordat to Support Research Integrity. Honest error and legitimate differences of scientific opinion are explicitly excluded.

    Do you need a research misconduct lawyer?

    Not every allegation requires a lawyer. A colleague’s informal query about a figure in a preprint, resolved by sending the underlying data, rarely needs legal input. A written allegation that triggers a formal screening or inquiry under an institution’s misconduct procedure is a different matter entirely.

    Engage counsel as soon as any of the following applies:

    • The allegation has been formally logged and a named investigation or inquiry panel has been convened.
    • Federal or funder money is involved, raising the possibility of debarment, clawback, or a fraud referral.
    • The outcome could affect employment status, tenure, or professional registration.
    • The institution’s own HR or disciplinary process is running in parallel with the research-integrity process.
    • Findings, if upheld, would likely require retraction of published work or notification to a journal or funder.

    A research misconduct lawyer does not replace the institution’s own procedure. Their role is to make sure that procedure is followed correctly, that evidence is preserved and properly interpreted, and that the respondent’s side of the record is documented at every stage — screening, inquiry, investigation, and any appeal.

    What happens during a research misconduct investigation?

    Most frameworks — UK and US alike — separate a misconduct case into a preliminary screening stage and a fuller inquiry, followed by a formal investigation and an appeal if findings are contested. The exact labels and thresholds differ by jurisdiction and by institution, which is itself a source of confusion for respondents.

    In the UK, there is no single statutory regulator equivalent to the US Office of Research Integrity (ORI). Each research organisation runs its own procedure, historically modelled on the UK Research Integrity Office (UKRIO) template. UKRIO’s 2023 publication, Procedure for the Investigation of Misconduct in Research, was formally sunset and replaced in December 2025 by a revised document titled Detailed procedure for investigating breaches of research integrity — a change institutional policy owners should check their references reflect. UK Research and Innovation (UKRI) also published dedicated guidance for research organisations on investigating research misconduct in April 2025, which states that institutional procedures “should be developed and reviewed in light of, and be consistent with, the Concordat to Support Research Integrity.”

    In the US, misconduct involving Public Health Service-funded research is governed by federal regulation at 42 CFR Part 93, which sets a three-stage process of inquiry, investigation, and adjudication, with ORI oversight and a defined right of appeal.

    Aspect US (PHS/ORI-funded research) UK (institution-led)
    Governing framework 42 CFR Part 93; ORI oversight No single regulator; institutional procedures aligned to the Concordat to Support Research Integrity and UKRI guidance
    Typical phases Inquiry → investigation → adjudication → appeal Screening → inquiry/initial assessment → formal investigation → appeal
    Standard of proof Preponderance of the evidence Balance of probabilities (the standard civil test used across most institutional procedures)
    Right to be accompanied Institution-dependent; counsel’s role at interviews is often advisory only Statutory right to be accompanied at a formal disciplinary hearing (Employment Relations Act 1999)

    The practical consequence for a respondent is definitive: know which framework applies to your case before assuming what your lawyer can and cannot do in the room.

    What rights does a respondent have?

    Due process protections for an accused researcher exist precisely because a misconduct finding can end a career. A fair procedure gives the respondent the opportunity to see and answer the case against them before any finding is made.

    Core respondent rights typically include:

    • Written notification of the specific allegations and the evidence supporting them.
    • A named point of contact and a reasonable timeframe to prepare a response.
    • The opportunity to submit evidence, nominate witnesses, and comment on a draft report before it is finalised.
    • Confidentiality of the process, so far as is consistent with a fair and thorough investigation.
    • A right of appeal against adverse findings or disproportionate sanctions.

    In the UK, employees have a statutory right under the Employment Relations Act 1999 to be accompanied at a formal disciplinary hearing by a colleague or trade union representative; a legal representative is not automatic and depends on the institution’s own procedure and the seriousness of the case. This is a materially different arrangement from many US institutional processes, where legal counsel may attend interviews but is frequently restricted to an advisory role rather than direct advocacy before the panel.

    Whose responsibility is it to report misconduct?

    Under the Concordat to Support Research Integrity, responsibility for identifying and reporting suspected research misconduct is shared, not delegated to a single office. Researchers, supervisors, co-authors, and institutions each carry a duty to raise a genuine concern through the correct channel rather than resolve it informally or ignore it.

    This shared-responsibility model has a direct consequence for anyone accused: the person who raised the concern may be a co-author, a journal editor acting on a reader’s tip, a funder’s compliance team, or an internal whistleblowing route — each of which triggers a different entry point into the institution’s procedure, and each of which a research misconduct lawyer will want identified early, since it shapes what evidence already exists before the respondent is even notified.

    Common questions about research misconduct allegations

    Who investigates allegations of research misconduct?

    In the UK, the employing research organisation investigates, typically through an inquiry panel or investigation committee constituted under its own procedure. In the US, institutions conduct the inquiry and investigation, with the federal Office of Research Integrity overseeing PHS-funded research and adjudicating contested findings.

    What counts as research misconduct?

    Research misconduct is fabrication, falsification, or plagiarism in proposing, conducting, reviewing, or reporting research. Some institutional frameworks add serious deviation from accepted practice or failure to secure required ethical approvals, but honest error and legitimate differences of scientific opinion are explicitly excluded from every recognised definition.

    What is considered the most serious form of research misconduct?

    Fabrication — inventing data outright — and falsification — manipulating materials, equipment, or data so the record is inaccurate — are generally treated as the most serious categories, because they corrupt the research record itself rather than misattributing credit, which is the harm caused by plagiarism.

    Whose responsibility is it to identify and report research misconduct?

    Under the UK’s Concordat to Support Research Integrity, every researcher, supervisor, and institution shares responsibility for identifying and reporting suspected misconduct. There is no single national regulator, so each employer’s own procedure — typically aligned to UKRI guidance — governs how, and to whom, a concern must be formally raised.

    For an accused researcher, the practical implication of all this is straightforward: engage legal counsel as soon as a formal allegation exists, confirm which procedural framework governs the case, and insist on the written notice, response time, and appeal rights that framework guarantees. As UKRIO’s December 2025 procedure revision and UKRI’s 2025 guidance both illustrate, the rules themselves continue to evolve — a respondent’s best protection is a lawyer who tracks which version currently applies, not the version that applied when the institution’s policy was last printed.

    For related definitions and process context, see the CASRAI Dictionary and the broader research administration resource hub.

  • Research Integrity Statements: How They Compare

    A research integrity statement is the annual public report a UK university publishes under the Concordat to Support Research Integrity, covering its governance, training and misconduct-handling activity. Depth of disclosure varies sharply: some institutions publish only a principles statement, while others — including the Open University in its 2026 statement — publish allegation tallies and investigation outcomes.

    A research integrity statement is defined by Universities UK’s Concordat as a governing-body-approved annual account of the steps an institution has taken to maintain rigour, transparency, honesty, and accountability in research, alongside a summary of misconduct allegations handled during the reporting year.

    What does the Concordat require in an annual statement?

    The Concordat to Support Research Integrity, coordinated by Universities UK and now overseen by the UK Committee on Research Integrity (UKCORI), requires every signatory to publish an annual statement approved by its governing body. Signatories are transitioning to the refreshed 2025 edition of the Concordat, with full alignment expected by April 2026; until that point, institutions continue reporting against the 2019 edition’s requirements.

    Under both editions, the statement must be publicly accessible on the institution’s website and must include an anonymised account of allegations of research misconduct received and how they were resolved. UKRIO’s self-assessment tooling encourages — but does not mandate — a common template, which is precisely why disclosure quality diverges so widely between institutions.

    • Approval by the university’s governing body (council, senate or board)
    • A narrative on training, culture and support for researchers
    • An anonymised summary of misconduct allegations and outcomes
    • Public web publication, with a copy sent to the Concordat secretariat

    Worked example: the Open University’s 2026 statement

    The Open University’s Research Integrity Statement 2026, approved by OU Council on 3 March 2026, covers the reporting period 1 October 2024 to 30 September 2025. It names Professor Mark Brandon, Pro-Vice-Chancellor for Research and Innovation, as senior lead, with Helen Castley, Senior Manager for Research Governance, as first point of contact.

    The statement discloses three misconduct allegations during the period, none of which proceeded to a formal investigation and none of which were upheld. It also reports the launch of an online research integrity module for postgraduate researchers in autumn 2024, sector-facing open research training, and the university’s signing of the Concordat for Environmental Sustainability of Research. Oversight sits with the Human Research Ethics Committee, an Ethical Research Review Committee, and a newly established Animal Ethics Committee.

    This is a useful baseline because it demonstrates the minimum viable version of Concordat compliance: named accountable officer, dated approval, allegation count, and training update — without case-level detail.

    How does disclosure depth compare across the sector?

    Compliance with the Concordat’s letter does not guarantee comparable transparency. Some institutions publish case-by-case misconduct tables; others confine the public statement to principles and point auditors to an internal report instead.

    Institution Approving body Misconduct data disclosed Training disclosure
    Open University OU Council Allegation count (3), zero formal investigations, none upheld New PGR online integrity module, autumn 2024
    University of Manchester Research Compliance Committee, reporting to Planning and Resources Committee Case-level table (e.g. 7 cases logged in the 2022-23 statement, with faculty, nature and outcome) Mandatory 5-hour course for PGRs, 1-hour course for staff, repeated every 3 years
    University of Cambridge General Board of the Faculties Not published on the public statement page; misconduct reporting sits in a separate Research Integrity Report to Council References Guidelines on Good Research Practice; no published hours or frequency

    The gap is stark: Manchester’s public statement lists individually anonymised case outcomes and quantifies training hours and frequency, while Cambridge’s equivalent page sets out principles and policy links without allegation figures in the same document. The Open University sits between the two, disclosing an allegation count and outcome but not case-level detail.

    For institutions and researchers assessing an organisation’s research misconduct policy or the maturity of its research integrity office, this variance matters more than whether a statement exists at all — a published statement with no allegation data offers limited assurance compared with one that itemises outcomes.

    What should a fully compliant statement include?

    Institutions revising their statement ahead of the April 2026 alignment deadline for the refreshed Concordat should treat the following as a minimum disclosure standard, based on the strongest examples in the sector.

    • Governing-body approval date and named senior accountable officer
    • Defined reporting period (financial or academic year)
    • Anonymised allegation count, broken down by outcome (informal resolution, formal investigation, upheld/not upheld)
    • Description of research integrity training provision, ideally with hours, frequency and audience (staff vs postgraduate researchers)
    • Governance structure — named committee(s) and their reporting line to council or board level
    • Reference to the institution’s research misconduct policy and how allegations are triaged
    • A statement on the consequences of research misconduct applied where allegations are upheld

    Frequently asked questions

    What is an example of a research integrity statement?

    The Open University’s 2026 statement is a working example: approved by OU Council on 3 March 2026, it reports three misconduct allegations, zero formal investigations, and new postgraduate training, alongside named senior accountability under the Concordat.

    What are the five principles of research integrity?

    Universities UK’s Concordat framework, as adapted across UK institutions, defines five core principles: honesty, rigour, transparency and open communication, care and respect for participants and colleagues, and accountability for one’s own research conduct.

    Does a research integrity statement have to report misconduct numbers?

    Yes — the Concordat requires an anonymised summary of misconduct allegations and outcomes in every annual statement. However, no single template is mandatory, so the level of detail — from a bare count to full case tables — varies significantly between institutions.

    Who approves a university’s annual research integrity statement?

    The Concordat requires approval by the institution’s governing body — typically a council, senate or board of governors — often via a delegated committee such as a research compliance or research integrity committee, before public web publication.

    What this means for research administrators

    As institutions align with the refreshed 2025 Concordat ahead of the April 2026 deadline, the sector faces a choice between minimum-viable compliance and genuine transparency. A statement that discloses only principles, with allegation data held back in an internal report, technically satisfies the Concordat’s publication requirement but tells funders, partners and prospective researchers little about how misconduct is actually handled.

    Research administrators drafting or revising a statement should benchmark against Manchester’s case-level disclosure rather than the sector floor, and should treat training hours, frequency and audience as reportable metrics, not narrative colour. Institutions publishing thin statements risk being read — correctly — as less mature on research governance than peers with equivalent misconduct rates but fuller disclosure.

    For research administration teams building out governance documentation more broadly, CASRAI’s research administration resources and research terminology dictionary provide further grounding in the frameworks referenced above.

  • ESRC Research Ethics Framework Explained: What It Requires of Institutions

    The ESRC Research Ethics Framework is UK Research and Innovation’s principles-based standard for ethics governance of Economic and Social Research Council-funded social science research. It sets out six core principles, requires researchers to self-assess risk, and delegates formal ethics review to independent institutional Research Ethics Committees (RECs) rather than centralising approval at ESRC. Institutions building or auditing an ethics-review process need to understand exactly what the framework requires of them, not just of researchers.

    The ESRC Research Ethics Framework (FRE) is UK Research and Innovation’s standard setting out what ESRC-funded social science research must satisfy to secure ethical approval, most recently updated on 12 May 2025.

    What is the ESRC Research Ethics Framework?

    The ESRC Research Ethics Framework is a policy document, not legislation. It applies as a mandatory condition of ESRC grant funding and is separately recommended by UKRI as good practice for social science research more broadly. The Economic and Social Research Council has operated as one of UK Research and Innovation’s nine constituent councils since UKRI’s creation under the Higher Education and Research Act 2017, effective 1 April 2018, and the framework is now published and maintained on the ukri.org domain rather than a standalone ESRC site.

    Crucially, the framework does not create a central ESRC approval process. It sets minimum principles and expectations, then places the operational burden of ethics review onto the researcher’s own institution — the “research organisation” in UKRI’s terminology — via a locally-run REC.

    What are the framework’s six core principles?

    UKRI’s current framework text lists six principles that anchor every ethics judgement made under the framework, whether by a researcher, a REC, or the research organisation itself:

    • Research should aim to maximise benefit for individuals and society and minimise risk and harm.
    • The rights and dignity of individuals and groups should be respected.
    • Wherever possible, participation should be voluntary and appropriately informed.
    • Research should be conducted with integrity and transparency.
    • Lines of responsibility and accountability should be clearly defined.
    • Independence of research should be maintained, and where conflicts of interest cannot be avoided they should be made explicit.

    These principles apply across the full research lifecycle — design, funded delivery, knowledge exchange, dissemination, and the archiving or future re-use of data — not just at the point of initial approval.

    How does the self-assessment and proportionate review model work?

    The framework uses a proportionate, self-assessment-led model. The researcher is initially responsible for judging the ethical risk profile of their own project against the six principles before submission. The institutional REC then confirms or overrides that judgement and assigns the review track. Every piece of ESRC-funded research must clear at least a light-touch review; nothing is exempt by default.

    Review type When it applies Who conducts it
    Light-touch review Minimal risk of harm; standard methods, non-vulnerable participants REC chair or a delegated sub-committee, often checklist-based
    Full review Vulnerable groups, sensitive topics, higher-risk methodologies, or unclear risk Full Research Ethics Committee

    In practice, the review sequence follows a consistent order:

    1. Researcher completes a self-assessment against the six principles and proposes a review track.
    2. Proposal, participant information sheets, and consent materials are submitted to the institutional REC.
    3. The REC assesses proportionality and either confirms light-touch clearance or escalates to full review.
    4. The REC issues a decision — approval, requested modifications, or, rarely, rejection on ethical grounds.
    5. The institution maintains ongoing oversight for the life of the project, not just at the approval stage.

    What must an institutional Research Ethics Committee do?

    Because ESRC delegates review rather than performing it centrally, the framework places explicit governance obligations on the REC itself, not only on the researcher. An institution cannot satisfy the framework merely by having a committee that exists on paper.

    • Independence — the REC must be free from undue influence by the institution, individual researchers, or members’ personal or financial interests.
    • Composition — membership should be diverse, spanning relevant methodological expertise, and should typically include lay members to provide a non-specialist perspective.
    • Clear terms of reference — the institution must document the committee’s authority, scope, and appeals procedure.
    • Accountability — the REC answers to the institution, and the institution in turn answers to ESRC for the ethical conduct of the research it has funded.
    • Monitoring capacity — the institution is expected to track REC performance and the ongoing conduct of approved projects, not treat approval as a one-off event.

    Scholarly merit is explicitly not the REC’s concern under this framework; that assessment sits with peer review at the funding-decision stage, keeping the ethics committee focused solely on risk, consent, and participant welfare.

    How does the framework interact with the Concordat to Support Research Integrity?

    UKRI states the framework is complementary to, not a substitute for, the Universities UK Concordat to Support Research Integrity, first published in 2012 and revised in 2019. The two instruments operate at different levels: the Concordat sets institution-wide commitments — rigour, transparency, responsible governance, addressing misconduct — that any UK research organisation signs up to across all disciplines, while the ESRC framework supplies the discipline-specific mechanics of ethics review for social science projects.

    For a research administrator, this means institutional ethics governance cannot be built from the ESRC framework alone. A REC operating under the framework should sit inside a wider integrity structure that also satisfies Concordat commitments — a named integrity lead, a misconduct-investigation procedure, and public reporting — so that ethics review and research-integrity assurance reinforce rather than duplicate each other.

    Answer-first Q&A

    Is ESRC ethics approval mandatory for all social science research?

    ESRC ethics approval is mandatory only for research the Economic and Social Research Council funds. For that funding, every application must clear at minimum a light-touch review; UKRI separately recommends the same six principles as good practice for social science research generally, even without ESRC funding.

    Who is responsible for ethics review under the ESRC framework?

    Ethics review is delegated to the applicant’s research organisation, not centralised at ESRC. Each institution must operate an independent Research Ethics Committee that assesses proposals against the six principles, assigns the review track, and remains accountable to ESRC for the outcome.

    What is the difference between light-touch and full ethics review?

    A light-touch review suits proposals carrying minimal risk of harm and can be cleared by a REC chair or sub-committee, often via checklist. A full review is required wherever research involves vulnerable groups, sensitive topics, or higher-risk methods, and needs assessment by the complete committee.

    Does the ESRC framework replace university ethics policies?

    No. The framework sets minimum principles and expectations; each research organisation still runs its own REC, terms of reference, and procedures. UKRI describes the guidance as complementary to the Universities UK Concordat to Support Research Integrity and to relevant professional-body guidelines, not a replacement for them.

    What this means for research administrators

    Building an institutional ethics-review process against this framework requires more than adopting the six principles as a preamble. Administrators need a documented REC with published terms of reference, a defined light-touch/full-review triage step, evidence of lay and methodologically diverse membership, and an ongoing monitoring mechanism that survives after initial sign-off. Institutions that treat the framework as a one-time approval gate rather than a lifecycle obligation risk falling short at ESRC audit or at REF-adjacent research-integrity checks.

    The framework’s proportionate, self-assessment-first design also means training matters as much as governance structure: researchers who cannot accurately self-assess risk generate REC backlogs and inconsistent triage decisions. Pairing the framework with clear institutional guidance — and aligning it explicitly with Concordat-level integrity commitments — is what separates a compliant REC from a merely nominal one. Research administration teams updating institutional policy should treat the two documents as a single governance stack, not two independent compliance exercises.

    Read more on research administration standards and frameworks shaping institutional compliance in UK social science research.

  • Research Integrity Office: A Governance Model

    A well-governed research integrity office reports to a senior academic officer independent of Human Resources, draws its investigation panels from cross-disciplinary senior staff plus at least one external member, and keeps case-handling separate from disciplinary sanctioning — a structure distinct from simply appointing a named Research Integrity Officer.

    A research integrity office is the standing institutional unit responsible for policy, training oversight and the inquiry-and-investigation process for allegations of research misconduct — distinct from the individually appointed Research Integrity Officer who runs its day-to-day casework.

    What Is a Research Integrity Office?

    A research integrity office is the standing unit — not a single job title — that owns an institution’s policy on responsible conduct of research, coordinates training, and runs the formal process when misconduct is alleged. Most coverage of this topic focuses on the individual Research Integrity Officer (RIO) career pathway; far less has been written about how the surrounding office should be structured as a governance function.

    The office typically sits alongside, but separate from, two adjacent functions: the research ethics committee, which reviews prospective study design and participant safeguards before research starts, and the research governance office, which manages sponsor, funder and regulatory compliance (common in clinical and health research). Conflating the three creates confusion about who owns what when a concern is first raised.

    It is also worth distinguishing an institution’s own office from the UK Research Integrity Office (UKRIO), an independent charity established in 2006 that provides advisory support — including case advice and training — to around 160 subscribing UK research organisations. UKRIO is a sector-wide advisory body; it does not replace the internal office each institution is expected to run under the Concordat to Support Research Integrity.

    Where Should the Office Report? Comparing Reporting-Line Models

    The office should report to a senior academic officer — a Pro-Vice-Chancellor for Research, Provost, or Vice-President for Research — never through a line that also manages HR casework or sits inside a single faculty. This gives the office standing to investigate any member of staff, including senior leadership, without a structural conflict of interest. In the United States, 42 CFR Part 93 requires any institution receiving Public Health Service research funding to designate an RIO with documented authority to act independently of the respondent’s own management chain.

    Governance model Reporting line Independence from HR Best fit
    Centralised office Reports directly to Provost / PVC-Research High — own budget line and case files Large, research-intensive universities
    Devolved faculty network Faculty-based integrity advisors report to a central RIO, who reports to the Provost Medium — depends on the advisor’s own line management Multi-faculty institutions with devolved research cultures
    External advisory subscription Advisory only; the institution retains formal decision-making authority High for advice, but not a substitute for a named internal Officer Smaller institutions, or as an escalation and second-opinion route

    King’s College London illustrates the devolved model: its Research Integrity Office is supplemented by faculty-based “Research Integrity Champions and Advisors” who provide local, first-line support while formal casework remains with the central office. Whichever model is chosen, the reporting line — not the job title of the person running it — determines whether the office can act without institutional pressure.

    Who Should Sit on the Investigation Panel?

    An investigation panel needs disciplinary expertise, distance from the respondent’s own department, and — for serious cases — at least one external, cross-institutional member. It should not include a standing HR representative as a voting member, because the panel’s task is to determine whether fabrication, falsification or plagiarism occurred, which is a different test to the workplace-conduct standard HR applies in disciplinary proceedings.

    • Cross-disciplinary membership that avoids conflicts of interest with the respondent’s own department or research group
    • At least one external member drawn from outside the institution for investigation-stage (not preliminary assessment-stage) cases
    • Separated roles across stages: an initial assessor, a fact-finding inquiry panel, and — only where warranted — a formal investigation committee
    • A documented recusal process for declared conflicts of interest
    • An independent secretariat, provided by the research integrity office itself rather than by HR

    Panel members require training on the institution’s misconduct policy and, where applicable, national frameworks such as the UKRIO Code of Practice for Research, which sets out five core principles — honesty, rigour, transparency and open communication, care and respect, and accountability — as the basis on which allegations are assessed.

    Why Independence from HR Is Non-Negotiable

    Independence from HR matters because a misconduct investigation establishes a factual finding about the integrity of the research record — a different exercise to the reasonable-conduct standard HR applies in employment disciplinary proceedings. Conflating the two risks the investigation being challenged as procedurally unfair, or as a pretext for an unrelated employment dispute.

    The two functions are sequential, not parallel. UK institutional codes typically specify that HR-led disciplinary procedures begin only once a research integrity office has confirmed a misconduct finding through its own separate process; King’s College London’s published Code of Good Conduct in Research is a public example of an institution setting out both processes as distinct. Confidentiality is a further reason for separation: misconduct proceedings protect the reputations of complainants, respondents and witnesses alike, and narrowing the circle of people with case access — rather than routing it through a general HR caseload — helps preserve that.

    Frequently Asked Questions

    What Does a Research Integrity Office Do?

    A research integrity office owns institutional policy on responsible research conduct, coordinates training for staff and students, and manages the formal process — assessment, inquiry and, where warranted, investigation — for allegations of research misconduct. It reports outcomes to senior leadership but does not itself impose employment sanctions.

    What Is the UK Research Integrity Office, and How Is It Different from an Institutional Office?

    UKRIO is an independent UK charity, established in 2006, that advises around 160 subscribing institutions and helped develop the Concordat to Support Research Integrity. It is a sector-wide advisory body, not a substitute for the internal office each institution must run to handle its own cases.

    What Are the Five Principles of Research Integrity?

    Under the UKRIO Code of Practice for Research, the five commonly cited principles are honesty, rigour, transparency and open communication, care and respect, and accountability. These principles inform how research integrity offices and panels assess whether an allegation meets the threshold for a formal misconduct finding.

    What Counts as Research Misconduct?

    Research misconduct generally covers fabrication, falsification and plagiarism, alongside proceeding without required ethical approvals and manipulating data, materials or processes to misrepresent results. A research integrity office defines the precise scope in institutional policy, aligned to national frameworks such as the Concordat to Support Research Integrity.

    Implications for Institutions Building or Reforming an Office

    The revised Concordat to Support Research Integrity (2025) sharpens its fifth commitment — accountability and continuous improvement — which puts explicit pressure on institutions to evidence, not merely assert, that their office structure is independent in practice. Institutions still relying on an RIO who reports through a research-office middle layer, or panels that include HR as a standing member, should treat this as a governance gap to close rather than an administrative preference.

    The wider research administration function increasingly treats research integrity governance as core infrastructure rather than a compliance afterthought, alongside ethics review and research governance offices. As AI-assisted data analysis and image manipulation raise new detection challenges, panels with genuine cross-disciplinary and external representation — reporting through a line insulated from both departmental and HR pressure — will be better placed to investigate credibly and defend their findings if challenged.

  • Researcher Development Concordat Action Plan

    The Researcher Development Concordat is a UK-wide agreement, first adopted in 1996 and substantially revised in 2019, that commits universities, research institutes, funders, and researchers to improving research culture, employment conditions, and career development for researchers. It is a distinct instrument from the Concordat to Support Research Integrity: the Researcher Development Concordat governs how researchers are supported and developed, not how research itself is conducted or investigated for misconduct. Signatory institutions report against it through a defined gap-analysis, action-plan, and annual-reporting cycle described below.

    The Researcher Development Concordat (formally “the Concordat to Support the Career Development of Researchers”) is administered by the Researcher Development Concordat Strategy Group (RDCSG), a UK-wide governing body drawing representatives from funders, higher education institutions, and sector bodies including UK Research and Innovation (UKRI), Research England, and the Scottish Funding Council.

    What is the Researcher Development Concordat?

    The Researcher Development Concordat traces back to a 1996 agreement, A Concordat to Provide a Framework for the Career Management of Contract Research Staff in Universities and Colleges, negotiated between UK funding bodies and universities. It was substantially rewritten and relaunched in September 2019 under its current name and structure, and remains a living, voluntary agreement rather than statutory regulation.

    Signatory institutions — the large majority of UK universities, plus a number of independent research institutes, funders, and regulators — commit to embedding the concordat’s principles in policy and practice. The concordat sits within the UK government’s wider R&D People and Culture Strategy (2021), which set an ambition of attracting and retaining an additional 150,000 researchers across the UK R&D system by 2030.

    Researcher Development Concordat vs the Concordat to Support Research Integrity

    These two UK concordats are frequently confused because both use the word “concordat” and both apply to universities and research institutes. They govern different things entirely, and institutions typically report against them through separate processes and to separate bodies.

    Aspect Researcher Development Concordat Concordat to Support Research Integrity
    Subject Researcher careers, employment, environment and culture Rigour, transparency and misconduct-handling in research conduct
    Origin 1996 (as the contract research staff concordat); revised 2019 First published 2012 by Universities UK; most recently revised 2025
    Governing/host body Researcher Development Concordat Strategy Group (RDCSG); secretariat: Universities UK UK Committee on Research Integrity (UKCORI), with the UK Research Integrity Office (UKRIO) providing advisory support
    Reporting mechanism Gap analysis, action plan, then annual progress reports published on institutional websites Annual statement of compliance published on institutional websites, plus a self-assessment tool
    Typical institutional owner HR, researcher development, or research culture teams Research integrity officers / research governance teams

    An institution can be a signatory to one concordat without automatically being a signatory to the other, and the two reporting cycles run on independent timetables. Research administrators should not assume compliance with one satisfies obligations under the other.

    The three principles and who is responsible for what

    The Researcher Development Concordat is structured around three defining principles, each carrying distinct obligations for four stakeholder groups: researchers, managers of researchers, institutions, and funders.

    • Environment and culture — a positive, inclusive research environment that recognises the contribution of all researchers to the wider research endeavour.
    • Employment — fair, transparent recruitment, reward, and recognition, and appropriate employment conditions for researchers regardless of contract type.
    • Professional and career development — access to continuing professional development and support for career planning, within and beyond academia.

    The RDCSG has also committed to reporting annually to the relevant government minister and devolved administrations on national progress, publishing a UK implementation plan, and commissioning a major review of the concordat’s implementation approximately every three years.

    What institutions must report under the action plan

    Concordat reporting is deliberately “light-touch and flexible,” in the words of the Researcher Development Concordat’s own reporting guidance, but it is not optional for signatories. The cycle runs in three stages.

    1. Gap analysis. A new signatory compares existing policy and practice against the three concordat principles. Institutions that have already completed a gap analysis for the HR Excellence in Research Award (HREiR) can reuse that work.
    2. Action plan. Within one year of signing, the institution must draw up and publish an action plan setting out how it will close the gaps identified.
    3. Annual report. From the following year onward, the institution submits an annual report to its governing body (or equivalent authority) and publishes it on its own website. The due date is fixed to the month the action plan was originally published.

    Each annual report must, for each of the three principles, cover: organisational context and approach; strategic objectives and implementation plans; measures of success; actions taken and evaluation of progress; lessons learned and any resulting modifications; a forward look to the next reporting period; and a brief statement of the report’s internal approval process. The RDCSG collects and evaluates these reports centrally to track national progress.

    Institutions holding the HREiR Award and the Concordat signatory status simultaneously benefit from an alignment arrangement: in the year they renew their triennial HREiR Award, they may submit that same documentation to meet their Concordat reporting requirement instead of preparing a separate report — reducing duplicated administrative effort, an arrangement the RDCSG and Vitae have formalised specifically to lower institutional reporting burden.

    Answer-first Q&A

    What are the three principles of the Researcher Development Concordat?

    The three principles are environment and culture, employment, and professional and career development. Each principle carries specific responsibilities for researchers, managers of researchers, institutions, and funders, and each must be addressed separately in a signatory’s action plan and annual report.

    Who is the secretariat of the Researcher Development Concordat?

    Universities UK acts as secretariat to the Researcher Development Concordat Strategy Group, while Nottingham Trent University chairs the group. The RDCSG itself draws representatives from funders including UKRI, Wellcome, and the British Academy, plus sector and staff-association bodies.

    What is the concordat for research development?

    It is a UK-wide, voluntary agreement — formally the Concordat to Support the Career Development of Researchers — under which signatory institutions commit to improving the working environment, employment conditions, and career support available to researchers at every career stage.

    When is a signatory’s first action plan due?

    A new signatory must publish its action plan within one year of signing the concordat. The first annual report is then due roughly twelve months later, in the same calendar month the action plan was published, and every year thereafter.

    Implications for research administrators

    Because reporting due dates are anchored to each institution’s own action-plan publication date rather than a single national deadline, research administrators need to track their institution’s specific cycle rather than assume a fixed annual date shared across the sector. Institutions that also hold the HREiR Award should actively align the two reporting schedules where possible, as the RDCSG and Vitae explicitly encourage.

    Given the frequent conflation with the Concordat to Support Research Integrity, institutions should ensure governance documentation clearly names which concordat a given policy, committee, or report addresses — misattribution creates real risk of a compliance gap being missed in an external review or funder audit. As the UK’s R&D People and Culture Strategy continues to shape funder expectations toward 2030, expect closer scrutiny of published action plans as evidence of institutional commitment, not just of formal signatory status.

  • Research Misconduct Investigations: How ORI and UKRIO Procedures Compare

    Grant administrators rarely encounter research misconduct allegations often — but when one arrives, the clock starts immediately, and the procedural path depends entirely on which side of the Atlantic the funding sits. A US Public Health Service (PHS) grant triggers a federally regulated process overseen by the Office of Research Integrity (ORI); a UK Research England or UKRI grant triggers an institution-led process shaped, but not enforced, by the UK Research Integrity Office (UKRIO). Confusing the two — assuming ORI’s binding timelines apply to a UK case, or that UKRIO can compel an outcome the way ORI can — is a common and costly error for administrators managing cross-border collaborations.

    This guide sets out, side by side, what each body actually is, how each defines misconduct, and how the investigation stages differ — so administrators handling an allegation tied to a grant know which rulebook applies.

    How ORI and UKRIO define research misconduct

    Both frameworks agree on a common core — fabrication, falsification, and plagiarism (FFP) — but they diverge sharply in scope.

    ORI operates under 42 CFR Part 93, the PHS Policies on Research Misconduct. Its definition is deliberately narrow: research misconduct means fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results. A finding requires three elements to be met: a significant departure from accepted practices in the relevant research community; committed intentionally, knowingly, or recklessly; and proven by a preponderance of the evidence. Honest error and legitimate differences of scientific opinion are explicitly excluded.

    UKRIO, by contrast, works from a broader, non-statutory definition: “behaviours that deliberately or recklessly fall short of the standards expected in the conduct of research.” Its guidance, aligned with the UK Concordat to Support Research Integrity (Universities UK, 2019), extends beyond FFP to cover breaches of ethical approval, undeclared conflicts of interest, and mismanagement of research data — while also naming a distinct, lower-severity category, “questionable research practices” (QRPs), for avoidable errors that fall short of intentional misconduct.

    Regulator versus adviser: two different roles

    The most consequential difference is not definitional but structural: ORI is a federal oversight body; UKRIO is an independent charity with no regulatory power.

    • ORI sits within the US Department of Health and Human Services and directly oversees how institutions handle misconduct allegations tied to PHS-funded research (including NIH grants). It can conduct its own oversight review of an institution’s findings, recommend administrative actions, and refer findings to the HHS Departmental Appeals Board.
    • UKRIO was established as an independent advisory charity in 2006. It publishes a model investigation procedure that UK research organisations may adopt or adapt, offers case-by-case advice, and promotes good practice — but it does not investigate cases itself, does not mandate a single national procedure, and has no statutory sanctioning power.

    UK funders address this gap contractually rather than through a regulator. UKRI’s Guidance for Research Organisations on the Investigation of Research Misconduct (April 2025) requires any organisation receiving UKRI funding to investigate allegations against staff or students under its own Grant Terms and Conditions, with UKRI able to take funding action if an organisation fails to do so.

    How an investigation actually runs, stage by stage

    Both systems separate a preliminary triage stage from a full inquiry, but they name and time these stages differently.

    Stage ORI (US, PHS-funded research) UKRIO model (UK institutions)
    Trigger Allegation received by institution’s Research Integrity Officer Concern raised with a “Named Person” or responsible officer
    Triage Assessment: does the allegation meet the FFP definition and involve PHS funding? Initial assessment: does it fall within the misconduct procedure’s scope?
    Formal fact-finding Inquiry (institution-level, time-limited) Initial investigation to establish if there is a case to answer
    Full review Investigation, following a sufficient inquiry finding Full investigation by an academic panel, including external members
    Standard of proof Preponderance of the evidence Not codified nationally; set by each institution’s procedure
    External oversight ORI oversight review of institutional findings; report to PHS agency None mandatory; UKRIO offers advice only
    Appeal route HHS Departmental Appeals Board Institutional appeal, managed by someone other than the original Named Person

    Under the UKRIO model, once a panel reports its findings, the Named Person decides on next steps: referral to institutional disciplinary proceedings, correction of the published record, and notifying relevant funders. Where allegations are not upheld, the same procedure is meant to protect the reputation of the person accused — a feature both systems share in principle, though neither publishes comparable statistics on false-allegation rates.

    Answer-first: common questions on research misconduct

    What are the three types of research misconduct?

    Both ORI and most UK institutional policies converge on the same core triad: fabrication (inventing data or results), falsification (manipulating research materials, equipment, or data to misrepresent results), and plagiarism (using another person’s ideas, processes, or words without credit). This is often abbreviated FFP.

    What are some examples of research misconduct?

    Common examples include inventing patient consent records, selectively deleting inconvenient data points, copying text or images from another paper without attribution, and misrepresenting the outcome of a statistical test. UKRIO guidance also treats proceeding without required ethical approval as a form of misconduct, even without FFP intent.

    What counts as research misconduct?

    Conduct counts as misconduct when it represents a significant, intentional or reckless departure from accepted research standards — not an honest mistake or a genuine scientific disagreement. ORI requires proof by a preponderance of the evidence; UKRIO-aligned institutions apply a similar intent-based threshold under their own procedures.

    What this means for research administrators

    For administrators managing grants that cross jurisdictions — a common scenario in NIH-funded international collaborations or Horizon Europe partnerships involving UK institutions — three practical points follow from the comparison above:

    • Know which body has enforcement power. Only ORI can conduct oversight review and refer a case to a federal appeals process; UKRIO cannot compel an institutional outcome.
    • Check the funder’s own reporting clause. UKRI’s April 2025 guidance obliges the receiving institution — not UKRIO — to investigate and report; PHS grant terms impose parallel obligations that run through ORI.
    • Do not assume a single global timeline. ORI-regulated inquiries and investigations run to defined federal timeframes; UKRIO-aligned UK procedures are set institution by institution, so the applicable deadline sits in the local Code of Practice for Research, not in UKRIO’s own documents.

    Administrators supporting research administration functions across both systems should hold copies of both the relevant institutional misconduct procedure and the specific grant terms — the procedural detail, not the high-level definition, is where jurisdictional mismatches cause delay.

    Where the two systems are heading

    Both frameworks are converging on the same underlying principle even as their governance models remain distinct: misconduct findings should correct the scholarly record, not just discipline an individual. UKRI’s 2025 guidance tightened institutional reporting obligations, and ORI continues to publish case summaries and administrative actions as a transparency mechanism. Neither change closes the structural gap — one system regulates, the other advises — so for the foreseeable future, administrators handling cross-border allegations will need to work both playbooks rather than assume one substitutes for the other.

    As with contributor-role standards, where CASRAI originated the CRediT taxonomy in 2014 and the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022, research integrity governance illustrates a broader pattern in research administration: originating bodies and enforcement bodies are frequently separate, and knowing which is which is a prerequisite for compliant practice.

  • UK Research Integrity Office vs US ORI: Comparing Oversight Models

    For institutions with staff, students, or funding on both sides of the Atlantic, understanding how research misconduct is handled is not an academic curiosity — it shapes compliance obligations, reporting duties, and reputational risk. The UK Research Integrity Office (UKRIO) and the US Office of Research Integrity (ORI) are the two most frequently cited reference points for research integrity oversight in the English-speaking research world, yet they sit at opposite ends of the regulatory spectrum: one advisory, one statutory. This analysis sets out what separates the UK’s Concordat-based, self-governing model from the US’s federally regulated assurance regime, and what that gap means in practice for institutions and publishers operating across both jurisdictions.

    Overview: two philosophies of oversight

    The UK has no statutory research-integrity regulator. Instead, oversight is distributed across independent charities, a voluntary sector-wide concordat, and each institution’s own governance. The US, by contrast, ties oversight of biomedical and behavioural research directly to federal funding: any institution receiving Public Health Service (PHS) money — chiefly through the National Institutes of Health (NIH) — must operate under enforceable federal regulation.

    This is the single most important distinction for anyone comparing the two systems: the UK model relies on reputational and contractual incentives to drive good practice, while the US model relies on funding-conditional legal compliance.

    The UK model: UKRIO, the Concordat, and self-governance

    UKRIO was established in 2006 as an independent charity. It offers confidential, impartial advice to researchers, institutions, and members of the public on good research conduct and on handling allegations of misconduct — but it does not investigate cases itself. That responsibility sits with the research organisation where the alleged conduct occurred, guided by UKRIO’s Code of Practice for Research.

    Sitting alongside UKRIO is the Concordat to Support Research Integrity, first published by Universities UK in 2012 and substantially revised in 2019. The Concordat is a voluntary framework, not legislation, built around five commitments:

    • Maintaining the highest standards of rigour and integrity in research
    • Conducting research in an appropriate, ethically sound, and legally compliant way
    • Supporting a research environment that is underpinned by a culture of integrity
    • Using robust and fair processes to investigate allegations of misconduct
    • Working openly and transparently, including public reporting on research integrity

    UK Research and Innovation (UKRI) and Research England are among the Concordat’s signatories, alongside the UK’s major research funders and universities. More recently, UKRI has moved to strengthen system-level coordination through a Committee on Research Integrity, intended to work alongside UKRIO on cross-sector oversight rather than to replace institutional responsibility — a signal that the advisory model is being reinforced rather than converted into a regulator.

    One point that is often glossed over: UKRIO’s Code of Practice defines misconduct more broadly than the classic fabrication-falsification-plagiarism (FFP) triad. It also covers matters such as proceeding without necessary ethical approval, misrepresenting data or authorship, and breaching a researcher’s duty of care — a wider net than the narrower legal definition used in the US.

    The US model: ORI and federal regulatory assurance

    The Office of Research Integrity sits within the US Department of Health and Human Services (HHS), under the Office of the Assistant Secretary for Health. Its jurisdiction is defined by federal regulation — 42 CFR Part 93 — and applies to institutions receiving PHS funding, which includes the large majority of federally funded biomedical and behavioural research in the United States.

    Unlike UKRIO, ORI operates within an assurance framework: institutions receiving PHS funds must file an institutional assurance confirming they have policies and procedures for handling misconduct allegations that meet federal standards. Institutions still conduct the initial investigation, but ORI reviews and can reopen or challenge that process. Where misconduct is confirmed, ORI can recommend administrative actions to HHS, ranging from supervision and certification requirements to debarment from federal funding — a consequence with no direct UK equivalent, since UKRIO has no power to withhold funding from anyone.

    Critically, the federal definition of research misconduct that ORI enforces is narrower than UKRIO’s: fabrication, falsification, and plagiarism (FFP) only, as set out in 42 CFR §93.103. Authorship disputes, data-management failures, or ethics-approval breaches that UKRIO would treat as misconduct concerns typically fall outside ORI’s formal jurisdiction, though they may still be handled under an institution’s own policies.

    Comparing the two models side by side

    Feature UK: UKRIO / Concordat US: Office of Research Integrity
    Legal status Independent charity; voluntary sector concordat Federal agency within HHS
    Established 2006 (UKRIO); 2012, revised 2019 (Concordat) 1992
    Governing basis No statute; reputational/contractual adoption Federal regulation, 42 CFR Part 93
    Investigatory role Advisory only; institutions investigate Reviews/oversees institutional investigations
    Misconduct definition Broader — includes ethics-approval and duty-of-care breaches Narrower — fabrication, falsification, plagiarism only
    Enforcement power None; promotes good practice via guidance Can recommend sanctions, including funding debarment
    Scope All disciplines, all UK research organisations PHS-funded biomedical/behavioural research
    Funding model Subscribing institutions pay for UKRIO’s services Federally funded as part of HHS budget

    Common questions on research integrity oversight

    What is the UK Research Integrity Office?

    The UK Research Integrity Office (UKRIO) is an independent charity, established in 2006, that provides expert advice and guidance on good research practice and the handling of misconduct allegations. It has no statutory or investigatory powers — responsibility for investigating allegations remains with individual research institutions.

    What does the US Office of Research Integrity do?

    The Office of Research Integrity (ORI) is a federal agency within the US Department of Health and Human Services. It oversees research-misconduct policy for Public Health Service-funded research, reviews institutional investigations, and can recommend administrative sanctions, including funding debarment.

    What counts as research misconduct under UKRIO’s Code of Practice?

    UKRIO’s Code of Practice for Research defines misconduct more broadly than fabrication, falsification and plagiarism alone, also covering breaches such as proceeding without ethical approval, misrepresenting data, and failing in a researcher’s duty of care — a wider net than the US federal definition.

    What are the core commitments of the Concordat to Support Research Integrity?

    The Concordat to Support Research Integrity, revised in 2019, sets out five commitments covering rigour and transparency, appropriate governance, a supportive research environment, robust misconduct investigation, and transparent public reporting — voluntarily adopted by UK universities and funders including UKRI.

    Implications for multinational institutions and publishers

    For institutions operating research programmes, joint ventures, or staff exchanges across the UK and US, the practical consequence of these two models is a compliance asymmetry. A collaboration that falls short of UKRIO’s broader Code-of-Practice standard may still be technically compliant with ORI’s narrower FFP definition, and vice versa — an ethics-approval lapse that UKRIO would flag as a misconduct concern may sit outside ORI’s formal jurisdiction entirely.

    • Research administrators managing joint UK-US grants should map both frameworks into a single institutional misconduct policy rather than defaulting to whichever funder’s rules are stricter on paper.
    • Publishers and journal editors handling cross-border authorship disputes should recognise that a “no finding” outcome from a US institution under ORI’s FFP standard does not necessarily mean the same conduct would clear UKRIO’s Code of Practice, or vice versa.
    • Funders operating in both jurisdictions benefit from Concordat-style transparent reporting commitments even where they are not legally required, since it narrows the gap with ORI’s assurance-based accountability.

    Outlook: converging pressures, diverging structures

    Neither system shows signs of formally converging. The UK’s 2019 Concordat revision and UKRI’s growing coordination role reinforce, rather than replace, the advisory model; the US assurance regime remains anchored in federal regulation that would require congressional or HHS rule-making to change materially. What is converging is expectation: international publishers, funders such as Horizon Europe, and bodies like COPE and the Committee on Publication Ethics increasingly expect institutions to demonstrate research-integrity governance regardless of which national model applies. For multinational institutions, the practical answer is not to wait for the UK and US to align, but to build internal policy that satisfies the stricter of the two standards on every point where they diverge.

  • Whose Responsibility Is It to Identify and Report Research Misconduct? UK and US Duties Explained

    Search interest in “whose responsibility is it to identify and report research misconduct” spikes around research-ethics coursework and institutional training, but the confusion it reflects is real and consequential. The honest answer is that whose responsibility it is to identify and report research misconduct depends on the role: the duty is shared, not singular, and it is formalised differently in the UK and the US. Principal investigators, co-authors, supervisors, peer reviewers, editors and institutional officers each hold a piece of the obligation, and neither UK nor US frameworks let any one of these roles opt out.

    This explainer sets out who owes a formal duty to report, which institutional office receives and manages that report, and what legal protection exists for the person who raises the concern.

    Who Carries the Individual Duty to Report?

    The starting point in both UK and US frameworks is that everyone involved in producing, reviewing or supervising research shares a duty of vigilance. A widely cited analysis of collaborative authorship, published in PMC (Helgesson et al., 2017), concludes that “every author shares the responsibility to be attentive to signs of misconduct” and is obliged to act if fraud or fabrication is suspected in a paper they co-author — co-authorship does not dilute individual accountability.

    In practice, the individuals expected to identify and escalate concerns include:

    • Principal investigators (PIs) — responsible for the conduct of their research programme and for acting on concerns raised by team members.
    • Co-authors and collaborators — expected to query irregularities in data, methods or results before a manuscript is submitted or published.
    • Supervisors of doctoral and early-career researchers — responsible for training on research standards and for reporting concerns about supervisees’ conduct.
    • Peer reviewers and journal editors — obliged under Committee on Publication Ethics (COPE) guidance to raise suspected fabrication, falsification or plagiarism (FFP) identified during review, rather than simply rejecting the manuscript.
    • Institutional Review Board / ethics committee members — responsible for flagging non-compliance with approved protocols.

    None of these roles constitutes the sole responsible party. That is the most common misconception behind the search query: there is no single “correct” answer among a multiple-choice list of individuals, because UK and US institutional policy assign the duty collectively.

    Institutional Duty: RIOs, Named Persons and Responsible Officers

    Once an individual raises a concern, formal responsibility shifts to a designated institutional office. The terminology and statutory basis differ between the UK and US, though the underlying model — an initial assessment, followed by a full investigation panel with external academic input — is similar in both systems.

    In the UK, the Concordat to Support Research Integrity (Universities UK, revised 2019) requires every signatory institution to have a published misconduct procedure and to designate a responsible individual — commonly titled the Named Person or Responsible Officer — to receive and triage allegations. UK Research and Innovation’s April 2025 guidance for research organisations goes further, requiring any organisation receiving UKRI funding to investigate allegations of research misconduct involving its staff or students, regardless of who funded the specific project in question. The UK Research Integrity Office (UKRIO) is not a statutory regulator; it is an independent advisory body that publishes a model procedure institutions can adopt or adapt.

    In the US, the equivalent office is the Research Integrity Officer (RIO), a role every institution receiving Public Health Service funding must designate under 42 CFR Part 93. The federal Office of Research Integrity (ORI), within the Department of Health and Human Services, oversees PHS-funded misconduct activity, defines fabrication, falsification and plagiarism (FFP) in federal regulation, and can review institutional findings on appeal.

    Aspect United Kingdom United States
    Sector-wide framework Concordat to Support Research Integrity (Universities UK, rev. 2019) 42 CFR Part 93 (HHS/PHS regulations)
    Designated institutional role Named Person / Responsible Officer Research Integrity Officer (RIO)
    Federal/national oversight body None statutory; UKRIO advises, UKRI mandates investigation for its grantees Office of Research Integrity (ORI), HHS
    Core definition used Fabrication, falsification, plagiarism and other serious deviations from accepted practice Fabrication, falsification, plagiarism (FFP) per 42 CFR §93.103
    Whistle-blower statute Public Interest Disclosure Act 1998 (amends Employment Rights Act 1996) Retaliation protections built into 42 CFR Part 93 institutional assurances

    Common Questions on Reporting Research Misconduct

    Who has the primary responsibility for investigating allegations of research misconduct?

    The host institution holds primary investigative responsibility, not the individual who raises the concern. A designated officer — the Research Integrity Officer in the US or the Named Person in the UK — triages the allegation, and a panel including external academic members conducts the full investigation if warranted.

    Who do you report research misconduct to?

    Concerns should go to the institution’s designated contact — typically the Research Integrity Officer, Named Person, or a supervisor/department head who escalates it formally. Many institutions also run confidential ethics or research-integrity hotlines for concerns raised anonymously.

    Who oversees research misconduct nationally?

    In the US, the Office of Research Integrity oversees PHS-funded misconduct activity on behalf of HHS. In the UK, no single statutory regulator exists; UKRIO provides advisory guidance and a model procedure, while UKRI mandates investigation as a funding condition for its grantees.

    What conduct counts as research misconduct under federal regulations?

    US federal regulation (42 CFR Part 93) defines research misconduct as fabrication, falsification, or plagiarism (FFP) in proposing, performing, or reviewing research, or in reporting results. Honest error and legitimate differences of scientific opinion are explicitly excluded.

    Whistle-Blower Protections: Reporting Without Retaliation

    Fear of retaliation is the most cited reason researchers stay silent about suspected misconduct, so both jurisdictions build legal protection into the reporting pathway.

    • UK: The Public Interest Disclosure Act 1998, which amends the Employment Rights Act 1996, protects workers who make a “protected disclosure” — including a reasonable belief that a legal obligation, such as a research or funding-body requirement, is being breached — from dismissal or detriment.
    • US: Institutions holding PHS funding must provide, as a condition of their assurance under 42 CFR Part 93, protection for complainants and witnesses against retaliation, and must diligently protect confidentiality where feasible during the assessment and inquiry stages.

    Institutional attribution practices also support accountability once an investigation is under way. Contributor role taxonomies used at submission — such as CRediT, which CASRAI originated in 2014 and which is now stewarded by NISO as ANSI/NISO Z39.104-2022 — make it easier for investigators to establish which named author was responsible for which specific contribution, rather than relying on blanket authorship credit. Research administrators building or reviewing misconduct procedures may find it useful to consult CASRAI’s overview of contributor role taxonomies and the individual CRediT roles alongside broader guidance on authorship standards.

    Implications for Research Administrators and Institutions

    For research administration offices, three practical implications follow from the shared-duty model:

    • Policy visibility matters as much as policy existence. The Concordat requires institutions not just to have a procedure but to publicise it to staff and the public — a written policy that nobody can find fails the spirit of Commitment 4.
    • Reporting channels need redundancy. Because responsibility is distributed across PIs, supervisors, co-authors and reviewers, a single named contact is not enough; institutions typically also need a confidential hotline route and a clear escalation path via department heads.
    • Investigation and disciplinary process must stay separate. UKRIO and ORI guidance both stress that the misconduct investigation determines what happened; any resulting disciplinary action is a distinct, subsequent process, with its own procedural safeguards.

    Institutions that receive UKRI funding should also note that the funder’s own guidance, updated in April 2025, requires investigation of allegations against staff or students as a condition of the funding relationship — independent of whether the specific allegation concerns a UKRI-funded project.

    A Shared, Structured Duty

    There is no single office or job title that owns research misconduct reporting end to end. Individual researchers — PIs, co-authors, supervisors and reviewers — carry a front-line duty to notice and escalate; a designated institutional officer (Research Integrity Officer in the US, Named Person or Responsible Officer in the UK) carries the duty to receive, triage and investigate; and national bodies (ORI in the US; UKRIO advisory guidance and UKRI funding conditions in the UK) set the framework both operate within. As funders sharpen their compliance requirements — UKRI’s April 2025 guidance being the most recent UK example — institutions should expect the expectation of distributed accountability, not a single responsible party, to keep hardening rather than simplifying.

  • Research Misconduct Statistics: What Springer Nature’s 2025 Retraction Data Reveal

    Springer Nature’s 2025 research-integrity disclosure landed with a number that cuts against the usual narrative: 1,462 retractions across its portfolio, roughly half the 2,923 logged in 2024. Read at face value, that looks like progress. Read against the underlying research misconduct statistics, it looks more like a legacy backlog being worked through than a crisis being resolved — 57% of 2025’s retractions (833 articles) were for papers published before January 2024, meaning the majority of this year’s corrections trace back to older, previously accumulated problems rather than newly discovered misconduct. For institutions, publishers and funders, that distinction changes the risk calculus considerably.

    Springer Nature’s 2025 Retraction Snapshot

    Springer Nature published these figures on its public research-integrity page, alongside its 2024 comparator, offering a rare year-on-year, publisher-disclosed dataset rather than a third-party estimate.

    Metric 2024 2025
    Total retractions 2,923 1,462
    Share for pre-cut-off papers 61.5% (1,797) — before Jan 2023 57% (833) — before Jan 2024
    Share for post-cut-off papers 38.5% (1,126) — after Jan 2023 43% (628) — after Jan 2024
    Post-cut-off retractions that were open access 41% ~21%
    Articles published that year 482,000+ 539,000
    Submissions received 2.3 million 3.1 million

    Set against roughly 539,000 primary research articles published in 2025, the 1,462 retractions represent under 0.3% of that year’s output — consistent with long-standing academic estimates that outright fabrication or falsification affects a small minority of the literature, even as absolute retraction counts have climbed industry-wide over the past decade.

    Backlog-Clearing or a Rising Tide?

    Two things are true at once. Springer Nature’s own retraction count fell by roughly half between 2024 and 2025. But the proportion attributable to legacy, pre-cut-off papers barely moved — 61.5% in 2024, still 57% in 2025 — which means well over half of each year’s retraction activity is publishers working backwards through their archive, not reacting to current misconduct.

    That pattern sits inside a wider industry trend. Nature reported that more than 10,000 papers were retracted across all publishers in 2023 — an all-time record at the time, driven substantially by mass clean-ups at journals compromised by paper mills. Springer Nature’s 2025 dip suggests one large publisher has made a dent in its own backlog, not that the sector-wide correction cycle has ended.

    • Legacy-paper retractions remained the majority share in both 2024 and 2025.
    • The open-access share of post-cut-off retractions nearly halved year on year (41% to ~21%), a data point worth monitoring rather than celebrating in isolation.
    • Springer Nature’s book-integrity investigations followed a similar arc: 124 in 2022, 207 in 2023, 217 in 2024, 210 in 2025, and 81 already by mid-April 2026 — prompting the publisher to introduce editorial expressions of concern for books in 2026.

    Root Causes: Paper Mills, Flawed Datasets and Peer-Review Fraud

    Springer Nature attributes its retractions to a recurring set of causes, echoed across the wider Retraction Watch record: data fabrication or falsification, plagiarism and duplicate publication, compromised or fraudulent peer review, unresolved authorship or consent issues, and the systematic activity of paper mills — commercial operations selling fabricated manuscripts or authorship slots.

    A live 2025 case illustrates how these risks travel across publishers. Springer Nature began retracting or removing 38 papers, conference proceedings and book chapters that trained neural networks on a dataset of children’s facial images scraped from autism-related websites without verifiable consent or diagnostic confirmation. Wiley had separately retracted two papers using the same dataset in 2023, and researchers identified at least 90 citing publications across the industry, with IEEE confirming an active investigation. One flawed dataset, multiple publishers, years of downstream exposure — a pattern institutional risk officers should recognise.

    What percentage of scientific papers are retracted?

    At Springer Nature, 1,462 retractions against roughly 539,000 articles published in 2025 equals under 0.3% of that year’s output. Broader academic surveys estimate outright misconduct — fabrication, falsification or plagiarism — affects between 0.3% and 4.9% of published research, depending on definition, discipline and detection method.

    Why are research papers retracted?

    Papers are retracted when the integrity of published work is substantially undermined — through data fabrication, plagiarism, compromised peer review, undisclosed authorship or consent problems, or paper-mill involvement. Retractions can also follow honest error, and are sometimes initiated by authors themselves once a flaw is confirmed, per COPE guidance.

    What is the difference between a retraction and an editorial expression of concern?

    An editorial expression of concern is an interim, indexed notice flagging serious unresolved concerns while an investigation continues. A retraction is the final editorial decision, made once integrity is confirmed as substantially compromised, following Committee on Publication Ethics (COPE) best-practice guidelines.

    What This Means for Institutional Risk Exposure

    Because well over half of each year’s retractions attach to papers published one, two or more years earlier, institutions cannot treat retraction risk as a current-cycle problem. Grant reports, tenure and promotion files, systematic reviews, and REF-style assessment submissions can all cite work that is retracted retroactively, with reputational and funding consequences that surface long after the original publication date.

    That is precisely why structured, per-contributor attribution matters. CASRAI originated the CRediT contributor role taxonomy in 2014; the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022. Where a CRediT contributor role statement clearly separates who ran the analysis, who supplied data, and who supervised the work, institutions and journals can isolate accountability far more precisely than a flat author byline allows — a distinction that becomes material the moment a co-authored paper is flagged. Research administration offices should treat this as core infrastructure, not paperwork: clear authorship documentation shortens investigation timelines and protects contributors who had no role in the disputed element of a paper.

    Publishers are also expanding scrutiny beyond journal articles. Springer Nature’s move to issue expressions of concern for books, after growing its book-related integrity probes from 124 to over 200 a year, signals that monograph and chapter output — historically under-scrutinised — now carries comparable institutional exposure to journal articles.

    Looking Ahead: How Institutions Should Respond

    Springer Nature’s figures update twice yearly, and the publisher has signalled that legacy-paper clean-up is an ongoing commitment rather than a one-off exercise — meaning the majority-legacy retraction pattern is likely to persist for several more reporting cycles. For research administration teams, that argues for a shift from reactive incident response to standing audit practice.

    • Audit legacy institutional outputs against publisher retraction and expression-of-concern notices, not just current submissions.
    • Require structured CRediT-style contributor statements on new submissions to enable faster, fairer accountability if a paper is later flagged.
    • Track publisher-level transparency pages (Springer Nature, and equivalents at other major publishers) alongside COPE guidance and the Retraction Watch database as standing monitoring sources.
    • Extend integrity oversight to books and monographs, not only journal articles, given publishers’ expanding scrutiny in this area.

    The headline number fell in 2025. The underlying research misconduct statistics say the correction cycle for legacy scholarship is far from finished — and institutions that plan accordingly, rather than reading a single year-on-year dip as resolution, will be better placed for whatever the next reporting cycle reveals.

  • Causes of Research Misconduct: Pressures, Metrics and Prevention

    What counts as research misconduct?

    Rising retraction counts and a steady stream of high-profile data-integrity cases have kept research misconduct on the agenda for research offices, funders and publishers well into 2026. The causes of research misconduct are rarely a single bad actor acting alone; they are usually a combination of individual choices and the incentive structures institutions build around publication, funding and promotion.

    The internationally recognised core definition, set out by the US Office of Research Integrity (ORI), covers three deliberate acts: fabrication (inventing data), falsification (manipulating data, materials or processes to misrepresent results), and plagiarism (using others’ ideas, words or results without credit) – together known as FFP. The UK Research Integrity Office (UKRIO) uses a broader definition that also captures breaches of ethical or legal obligations, such as unauthorised use of confidential data or failure to obtain proper approvals.

    FFP is distinct from questionable research practices (QRPs) – selective reporting, inappropriate authorship credit, or p-hacking – and from honest error. The distinction matters because prevention strategies differ: FFP requires deterrence and detection, while QRPs respond better to training, culture change and transparent reporting standards.

    The structural and incentive-driven causes of research misconduct

    A 2017 National Academies of Sciences, Engineering, and Medicine report, Fostering Integrity in Research, grouped the drivers of misconduct into six overlapping categories: career and funding pressures, institutional failures of oversight, commercial conflicts of interest, inadequate training, erosion of mentoring standards, and misconduct as part of a wider pattern of deviant behaviour. Subsequent survey research has consistently pointed to the same structural pressures rather than isolated moral failure.

    Holtfreter et al. (2020), surveying academics on the perceived causes of misconduct, found that professional strains and stressors – particularly the pressure to secure competitive grant funding – were cited most often, ahead of individual psychological factors. This lines up with a widely cited earlier synthesis: Fanelli’s 2009 meta-analysis of survey data found that around 2% of scientists admitted to fabricating or falsifying data at least once, while up to a third admitted other questionable research practices – and both figures rose substantially when respondents were asked to estimate colleagues’ behaviour rather than report on their own.

    “Publish or perish” culture and metrics gaming sit at the centre of the structural explanation. When journal impact factor, h-index, publication counts and grant income are used as proxies for quality in hiring, tenure and national assessment exercises, researchers face direct incentives to inflate output rather than rigour. Davis (2003) categorised the underlying factors into three levels, which remains a useful frame for institutional leaders diagnosing where their own controls are weakest.

    Causal level Example factors Where responsibility sits
    Individual Career ambition, financial pressure, poor ethics training, psychological stress Researcher, supervisor
    Organisational Weak oversight, inadequate mentoring, metrics-driven promotion criteria, under-resourced integrity offices Institution, department
    Systemic Publish-or-perish funding models, journal impact-factor incentives, low probability of detection, weak sanctions Funders, publishers, national assessment bodies

    Two systemic factors deserve particular attention from research administrators: low detection probability and weak penalties. A web-search-grounded synthesis of current literature commissioned for this article converged on the same point – academics themselves believe that a low likelihood of investigation, combined with inconsistent sanctions once misconduct is confirmed, is a significant driver of continued misconduct. This is an institutional-design problem, not only an ethics-training problem.

    Quick answers: types, drivers and consequences

    What are the three main types of research misconduct?

    The three internationally recognised categories are fabrication (inventing data or results), falsification (manipulating data, materials or processes to misrepresent findings), and plagiarism (using others’ ideas or words without credit). Together these form the “FFP” definition used by ORI and most national integrity bodies.

    What are the reasons for unethical research?

    Reported reasons include career and funding pressures, institutional failures of oversight, commercial conflicts of interest, inadequate training in research ethics, erosion of mentoring standards, and – in a minority of cases – misconduct forming part of a broader pattern of deviant behaviour, per the National Academies’ 2017 analysis.

    What are the 5 unethical practices in conducting research?

    Commonly cited categories are falsification of data, failure to credit others, plagiarism, undisclosed conflicts of interest, and biased design or interpretation driven by outside influence. Authorship misconduct – including honorary and ghost authorship – is frequently added as a sixth practice in institutional policies.

    What are the 5 main ethical issues in research?

    Beyond FFP itself, institutions most often flag informed consent failures, conflicts of interest, data management and privacy breaches, authorship disputes, and inadequate oversight of research involving human or animal subjects as recurring ethical issues requiring governance attention.

    Evidence-based prevention strategies for institutional leaders

    Because the causes are structural as well as individual, effective prevention combines training with changes to incentive design. Institutional leaders following frameworks from COPE, UKRIO and the UK Concordat to Support Research Integrity typically prioritise the following:

    • Decouple assessment from raw output metrics. Reduce reliance on publication counts and journal impact factor in hiring, tenure and internal funding decisions, in line with responsible-metrics initiatives such as DORA.
    • Fund and empower a dedicated integrity office. A resourced office that can investigate allegations promptly – and is seen to do so – directly addresses the “low detection probability” driver identified in the literature.
    • Make authorship transparent and auditable. Structured, taxonomy-based contributor statements reduce opportunities for honorary and ghost authorship. CASRAI originated the CRediT contributor role taxonomy in 2014; the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022, and its adoption by journals makes individual contributions explicit rather than assumed.
    • Strengthen mentoring and mandatory ethics training for early-career researchers, who are disproportionately exposed to supervision gaps.
    • Protect whistleblowers with clear, enforced anti-retaliation policies – a precondition for any self-reporting culture to function.
    • Apply consistent, proportionate sanctions once misconduct is confirmed, closing the gap between policy and enforcement that researchers themselves identify as a weakness.

    Implications for institutions, funders and publishers

    The practical implication is that misconduct prevention cannot sit solely within research ethics training. In 2023, Crossref and Retraction Watch partnered to integrate more than 43,000 retraction records into open, machine-readable metadata – a structural fix that makes retraction status discoverable at the point of citation, rather than relying on researchers to notice a correction years later. That kind of infrastructure-level intervention complements, rather than replaces, institutional oversight.

    For research administrators, the actionable shift is from a compliance mindset (“train researchers, then police them”) to a design mindset: audit which internal metrics reward speed over rigour, resource integrity offices adequately, and make authorship and contribution as transparent as data availability statements already are. Consult the CASRAI Dictionary for precise definitions when drafting or updating institutional misconduct policy, and review authorship guidance where disputes over credit are a recurring source of allegations.

    None of this suggests misconduct is inevitable. It suggests that where institutions have reduced metrics pressure, resourced oversight and made contribution transparent, the same literature that identifies the causes also points to measurable, achievable prevention.